Stopping GLP-1 Medications Can Quickly Erase Heart Benefits

A significant benefit of GLP-1 medications, initially prescribed for diabetes and increasingly used for weight loss, is a substantial reduction in the risk of heart attacks, strokes, and other cardiovascular problems. However, new research reveals that these heart benefits can be quickly lost when treatment is stopped.

Cardiovascular Risk Returns Within Months

A large study published in BMJ Medicine on March 18, 2026, found that heart risks begin to rise as soon as six months after discontinuing GLP-1 medication and may be almost completely reversed within a year and a half. Researchers followed over 333,000 U.S. Veterans with type 2 diabetes for three years, comparing those prescribed GLP-1s to those taking sulfonylureas, another type of diabetes medication.

Metabolic Whiplash and the Loss of Protection

Study author Dr. Ziyad Al-Aly, a clinical epidemiologist at the Washington University School of Medicine in St. Louis, describes the reversal of benefits as a “metabolic whiplash.” He explains that it takes considerably longer to build cardiovascular protection with GLP-1s than it does to lose it. “It takes a whole lot longer to build or accrue benefit, and then half as much to erase all that benefit,” he stated. Specifically, benefits accrued over three years of treatment can be undone in just 18 months after stopping the medication.

Study Findings: Increased Risk with Discontinuation

The study demonstrated a clear correlation between the duration of GLP-1 medication discontinuation and increased cardiovascular risk. Compared to those who continued the medication, individuals who stopped GLP-1 treatment experienced:

• A 4% increase in heart risks after six months.
• A 14% increase in risk after one year.
• A 22% increase in risk after two years, effectively erasing the initial benefits.

GLP-1s and Heart Health: Beyond Weight Loss

The findings align with results from the SELECT trial, which showed a 20% reduction in cardiovascular events in individuals taking semaglutide for obesity, even in those who did not experience weight loss CNN. This suggests that GLP-1 medications offer both weight-dependent and weight-independent benefits to the heart.

How GLP-1s Impact the Heart

While the exact mechanisms are still being investigated, GLP-1 medications are believed to improve cardiovascular health through multiple pathways. Weight loss associated with these drugs reduces inflammation. GLP-1 receptors are present on heart tissue, suggesting a direct effect of the medication on the heart mplsheart.org.

Reasons for Discontinuation and Insurance Concerns

Approximately half of individuals who begin taking GLP-1 medications discontinue use within one year, primarily due to side effects like nausea and fatigue, and the high cost of the drugs. Dr. Al-Aly emphasizes the need for insurance coverage to continue beyond initial weight loss goals, arguing that stopping the medication exposes patients to unnecessary cardiovascular risk. “Stopping has consequences to the heart,” he said. “Insurers need to realize that, you recognize, when they deny these things that actually exposing people to unnecessary risk.”

Future Research and Considerations

Further research is needed to determine whether maintaining weight loss after discontinuing GLP-1s can preserve some cardiovascular benefits, and whether lower maintenance doses can prevent the reversal of these benefits. However, the current evidence strongly suggests that continued treatment is crucial for sustained heart protection.